OakChart

BeOne Medicines Ltd ADR

ONCHealthcare·Biotechnology·Switzerland·Large·NASD·Nov 11 • 8:13 AM ET

424.000.00 (0.00%)
2026-11-11 14:56 CET
Market cap
44,640.84 USD m
Revenue, TTM
6,625.40 USD m
Net income, TTM
917.96 USD m
Free cash flow, TTM
1,452.89 USD m
EPS diluted, TTM
7.89
P/E
53.76
Compare

Price

ONC against its 20, 50 and 200-day averages
2050200beat
250.00300.00350.00400.00500K1.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ONCclose 424.0020-day 382.5050-day 367.10200-day 327.16424.00

2.4% under 434.63 on 11 Nov 2026. Last 15 sessions, 25.0% high to low

Profile

ONC
52-week range, 100% of the way up
253.95424.73

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Employees12000
IPOFeb 03, 2016
Beta0.61
ATR, 14d13.86
Rel volume1.15
Short float1.53%
Insider own0.53%
Inst own32.53%

Snapshot

6 groups

Valuation

Index-
Market Cap44.64B
Enterprise Value40.86B
Income917.96M
Sales6.63B
Book/sh51.01
Cash/sh55.51
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees12000
IPOFeb 03, 2016

Ratios

P/E53.76
Forward P/E40.26
PEG0.54
P/S6.74
P/B8.31
P/C7.64
P/FCF30.72
EV/EBITDA30.02
EV/Sales6.17
Quick Ratio3.19
Current Ratio3.55
Debt/Eq0.35
LT Debt/Eq0.29
Option/ShortYes / Yes

Earnings

EPS (ttm)7.89
EPS next Y10.53
EPS next Q2.58
EPS this Y222.76%
EPS next Y24.06%
EPS next 5Y74.28%
EPS past 3/5Y- -
Sales past 3/5Y55.88% 76.88%
EPS Y/Y TTM1272.97%
Sales Y/Y TTM33.13%
EPS Q/Q201.24%
Sales Q/Q33.99%
EarningsNov 05 BMO
EPS/Sales Surpr.70.95% 7.69%

Ownership

Insider Own0.53%
Insider Trans-66.04%
Inst Own32.53%
Inst Trans1.37%
ROA10.49%
ROE18.45%
ROIC12.24%
Gross Margin87.40%
Oper. Margin17.84%
Profit Margin13.86%
SMA2010.85%
SMA5015.50%
SMA20029.60%
Trades-

Technical

Shs Outstand105.25M
Shs Float104.73M
Short Float1.53%
Short Ratio3.94
Short Interest1.60M
52W High424.73 -0.17%
52W Low253.95 66.96%
Volatility3.56% 2.96%
ATR (14)13.86
RSI (14)72.78
Beta0.61
Rel Volume1.15
Avg Volume406.41K
Volume23,349

Performance

Perf Week12.23%
Perf Month21.46%
Perf Quarter19.10%
Perf Half Y33.94%
Perf YTD39.56%
Perf Year23.38%
Perf 3Y112.95%
Perf 5Y15.03%
Perf 10Y1216.77%
Recom1.27
Target Price463.23
Prev Close424.00
Price424.00
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 13, 2026UpgradeJJefferiesHold → Buy$380-10.4%
Mar 27, 2026InitiatedWWolfe ResearchOutperform$340-19.8%
Mar 16, 2026DowngradeJJefferiesBuy → Hold$290-31.6%
Nov 24, 2025InitiatedTTruistBuy
Sep 18, 2025InitiatedBBarclaysOverweight$385-9.2%
Apr 07, 2025InitiatedRRBC Capital MktsOutperform$312-26.4%
Mar 03, 2025UpgradeBBofA SecuritiesNeutral → Buy$207 → $320-24.5%
Dec 03, 2024ResumedMMorgan StanleyOverweight$300-29.2%
Sep 18, 2024InitiatedJJMP SecuritiesMkt Outperform$288-32.1%
Feb 06, 2024ResumedJJP MorganOverweight$185-56.4%

Peers

Mkt cap
TickerCompanyMkt cap
GMABGenmab ADR32.47B
INCYIncyte Corp23.64B
AZNAstrazeneca plc286.14B
ZLABZai Lab Limited ADR2.97B
SMMTSummit Therapeutics Inc14.33B
ABBVAbbvie Inc513.88B
BNTXBioNTech SE ADR21.76B
EXELExelixis Inc17.20B
LEGNLegend Biotech Corp ADR3.97B
MRKMerck & Co Inc361.64B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ball Titus B.Principal Accounting OfficerNov 06 '26Option Exercise186.421,559290,6251,559Nov 10 04:59 PM
Ball Titus B.Principal Accounting OfficerNov 06 '26Sale405.571,559632,2770Nov 10 04:59 PM
Lee Chan HenrySVP, General CounselNov 05 '26Sale400.821,115446,9100Nov 09 05:13 PM
TITUS BENJAMIN BALLOfficerNov 06 '26Proposed Sale405.571,559632,277Nov 06 05:11 PM
CHAN LEEOfficerNov 05 '26Proposed Sale377.781,115421,225Nov 05 04:31 PM
Wang XiaodongChair, Scientific Advisory BrdOct 27 '26Option Exercise36.9031,0281,144,93331,028Oct 29 05:04 PM
Wang XiaodongChair, Scientific Advisory BrdOct 27 '26Sale362.9731,02811,262,1310Oct 29 05:04 PM
Wang XiaodongChair, Scientific Advisory BrdOct 13 '26Option Exercise36.9031,0271,144,89631,027Oct 15 05:08 PM
Wang XiaodongChair, Scientific Advisory BrdOct 13 '26Sale350.9931,02710,890,0740Oct 15 05:08 PM
Lee Chan HenrySVP, General CounselSep 30 '26Sale375.001,115418,1250Oct 02 04:53 PM
Wang XiaodongChair, Scientific Advisory BrdSep 28 '26Option Exercise36.9031,0281,144,93331,028Sep 30 05:11 PM
Wang XiaodongChair, Scientific Advisory BrdSep 28 '26Sale364.7931,02811,318,5580Sep 30 05:11 PM
CHAN LEEOfficerSep 30 '26Proposed Sale365.271,115407,276Sep 30 04:20 PM
Wang XiaodongChair, Scientific Advisory BrdSep 08 '26Option Exercise36.9031,0271,144,89631,027Sep 10 04:49 PM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.47B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.05B
CGGOCapital Group Global Growth Equity ETFAUM: 11.80B
CGGECapital Group Global Equity ETFAUM: 3.27B
CGNGCapital Group New Geography Equity ETFAUM: 2.99B
CGIECapital Group International Equity ETFAUM: 2.48B
BBHVanEck Biotech ETFAUM: 536.31M
CANCTema Oncology ETFAUM: 217.09M
BGGGBaillie Gifford Long Term Global Growth ETFAUM: 250.55M
DFEMDimensional Emerging Markets Core Equity 2 ETFAUM: 8.70B

News

latest 14 of 206
  • BeOne Medicines Beats Big And Raises Guidance Again As BRUKINSA Tops $1 Billion In The U.S., But The 2027 Setup Gets Harder (Earnings Whispers)
  • BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates (Business Wire)
  • BeOne Medicines Receives FDA Priority Review for BRUKINSA Combination in First-Line Mantle Cell Lymphoma (InvestorsHub) +6.42%
  • U.S. FDA Grants Priority Review to BeOne Medicines BRUKINSA Combination in First-Line Mantle Cell Lymphoma (Business Wire)
  • BeOne Medicines to Present at the Jefferies Global Healthcare Conference (Business Wire)
  • Loading…
  • BeOne's Brukinza Momentum Faces Its Test As Street Sits At Low End Of Raised Guidance (Earnings Whispers)
  • BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 (Business Wire)
  • BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer (Business Wire)
  • BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well. (Investor's Business Daily)
  • BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5 (Business Wire)
  • BeOne Medicines to Present New Solid Tumor Clinical Data Across Four Priority Programs at ESMO 2026 (InvestorsHub)
  • BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 (Business Wire)
  • Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs (The Wall Street Journal) +6.43%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-053.2501.9013.2501,8901,75514
2026Q22026-08-052.0501.6612.0501,7051,62515
2026Q12026-05-061.9601.0761.9701,5131,43713
2025Q42026-02-260.6001.2440.5791,4981,46511
2025Q32025-11-061.0900.8511.0921,4121,36513
2025Q22025-08-060.9100.3870.8411,3151,24111
2025Q12025-05-070.000-0.5310.0121,1171,13211
2024Q42025-02-27-1.430-1.012-1.4241,1281,0458
2024Q32024-11-12-1.150-1.114-1.1551,002983.267
2024Q22024-08-07-1.150-2.189-1.149929.17810.349
2024Q12024-05-08-2.410-3.094-2.405751.65670.099
2023Q42024-02-26-3.530-3.489-3.556634.41637.018
2023Q32023-11-092.010-3.3852.014781.31596.757
2023Q22023-08-02-3.640-3.361-3.601595.26501.076
2023Q12023-05-04-3.340-3.663-3.338447.8444.26
2022Q42023-02-27-4.290-4.635-4.285380.1388.177

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-15.800-12.521-15.824428.21434.53
2020FY-19.130-17.275-19.164308.87332.54
2021FY-15.230-12.138-15.7331,1761,201
2022FY-19.430-18.147-19.4061,4161,413
2023FY-8.450-8.143-8.4392,4592,424
2024FY-6.110-5.398-6.1273,8103,716
2025FY2.6303.0072.6305,3435,302
2026FY-8.489--6,910
2027FY-10.531--7,971
2028FY-13.922--9,026
2029FY-15.962--9,897
2030FY-19.175--11,230

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06131111,8771,8351,951
2026Q4S2026-11-0513811,8531,7281,951
2026Q4S2026-11-0414201,7931,7281,881
2026Q4S2026-10-2014201,7931,7281,881
2026Q4S2026-10-1914401,7931,7281,881
2026Q4S2026-10-14141201,7931,7281,881
2026Q4S2026-10-11141101,7871,7281,837
2026Q4S2026-10-07141111,7871,7281,837
2026Q4S2026-10-05141111,7861,7281,837
2026Q4S2026-10-02141211,7861,7281,837
2026Q4S2026-09-30141211,7841,7281,837
2026Q4S2026-09-23141211,7851,7281,845
2026Q4S2026-09-11141311,7851,7281,845
2026Q4S2026-08-06141311,7851,7281,845

Estimate history

EPS, annual-1.565-11.273-15.824-19.164-15.733-19.406-8.439-6.1272.5367.8871
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.155-1.4240.0120.8411.0920.5791.972.053.288
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual239.196198.042428.949309.4061177.8441414.2392456.6423812.1525357.1646625.4
Period201720182019202020212022202320242025TTM
Sales, quarterly1009.8221123.7861118.871319.9761414.1751504.7081517.9511707.8881894.853
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual59.71359.71361.64291.602102.67795.10695.35997.626102.002105.251
Period201720182019202020212022202320242025MRQ
Shares, quarterly97.24897.62697.248101.011101.771102.002102.263104.171105.251
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue6,625.405,357.163,812.152,456.641,414.241,177.84309.41428.95198.04
Cost of Goods Sold Incl. D&A834.61788.63718.78463.45349.11210.68102.6289.9638.56
Gross Profit5,790.794,568.533,093.381,993.191,065.13967.17206.78338.99159.48
Selling, General and Administrative Excl. Other4,608.924,120.213,661.863,199.882,851.002,407.811,867.321,300.53864.61
Research and Development2,359.002,078.901,855.411,696.681,574.671,416.371,266.11911.61669.40
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1,181.86448.32-568.48-1,206.69-1,785.88-1,440.64-1,660.54-961.54-705.14
Interest Expense135.9758.3946.9220.7821.6729.300.000.000.00
Unusual Expense35.5674.7119.19-22.6528.68-7.600.000.000.00
Net Income Before Taxes1,134.31417.96-533.27-825.12-1,958.71-1,440.50-1,620.98-945.21-689.21
Income Taxes216.35130.26111.8455.8242.7319.25-17.707.00-15.78
Consolidated Net Income917.96287.69-645.11-880.94-2,001.43-1,459.75-1,603.28-952.21-673.43
Net Income From Continuing Operations917.96287.69-645.11-880.94-2,001.43-1,459.75-1,599.65-950.26-673.16
Net Income917.96287.69-645.11-880.94-2,001.43-1,459.75-1,599.65-950.26-673.16
EPS (Recurring)8.043.00-6.00-8.59-19.21-15.79-19.16-15.82-11.27
EPS (Basic, Before Extraordinaries)8.182.64-6.13-8.44-19.41-15.73-19.16-15.82-11.27
EPS (Diluted)7.892.54-6.13-8.44-19.41-15.73-19.16-15.82-11.27
EBITDA1,360.95590.38-396.64-1,119.09-1,719.68-1,394.13-1,628.69-942.89-695.25
Non-Operating Income (Expense)123.98102.74101.32379.70-122.4721.8539.5616.3315.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense409.52404.16349.19290.14239.21175.95137.85100.7965.29
Price To Earnings Ratio53.7653.76-------
Price To Sales Ratio6.486.435.107.6616.0421.3469.7123.2142.29
Gross Margin87.4085.2881.1581.1375.3182.1166.8379.0380.53
Operating Margin17.848.37-14.91-49.12-126.28-122.31-536.69-224.16-356.05
Net Margin13.865.37-16.92-35.86-141.52-123.93-517.01-221.53-339.91
Shares Outstanding105.25102.0097.6395.3695.11102.6891.6061.6459.71
Market Capitalization44,640.8444,640.8418,032.3917,190.3820,896.3227,730.5023,495.2010,009.908,347.74

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,894.851,707.891,517.951,504.711,414.171,319.981,118.871,123.79
Cost of Goods Sold Incl. D&A249.30208.28202.89174.14228.30191.83194.30190.85
Gross Profit1,645.551,499.611,315.061,330.561,185.871,128.15924.57932.94
Selling, General and Administrative Excl. Other1,225.761,174.031,064.411,144.721,022.541,039.95913.461,012.08
Research and Development644.36593.47521.31599.87505.42510.26463.62518.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income419.79325.58250.65185.84163.3388.2011.12-79.14
Interest Expense42.5239.8032.9920.6612.6712.0912.986.92
Unusual Expense0.66-5.07-0.0540.0214.235.040.009.00
Net Income Before Taxes411.45312.98259.99149.89147.3699.9020.93-85.05
Income Taxes25.7275.5831.9583.1022.355.2519.6666.29
Consolidated Net Income385.73237.40228.0366.79125.0194.661.27-151.34
Net Income From Continuing Operations385.73237.40228.0366.79125.0194.661.27-151.34
Net Income385.73237.40228.0366.79125.0194.661.27-151.34
EPS (Recurring)3.292.021.970.821.180.870.01-1.36
EPS (Basic, Before Extraordinaries)3.392.132.060.601.130.870.01-1.42
EPS (Diluted)3.292.051.970.581.090.840.01-1.42
EBITDA480.89366.17291.91221.98200.67123.9443.97-29.07
Non-Operating Income (Expense)34.8422.1242.2824.7410.9328.8422.7910.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense105.05108.7897.7497.96111.37119.3675.5184.84
Price To Earnings Ratio53.7663.59117.71584.47----
Price To Sales Ratio6.485.375.976.547.845.967.245.15
Gross Margin86.8487.8186.6388.4383.8685.4782.6383.02
Operating Margin22.1519.0616.5112.3511.556.680.99-7.04
Net Margin20.3613.9015.024.448.847.170.11-13.47
Shares Outstanding105.25104.17102.26102.00101.77101.0197.2597.63
Market Capitalization44,640.8429,151.5830,301.3333,608.0734,406.6126,530.8726,858.9918,032.39

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4,588.832,636.713,185.874,535.026,617.834,650.99983.021,795.97837.50
Short Term Receivables886.86709.10395.89198.98500.1679.6772.8152.7629.43
Inventories608.23494.98416.12282.35242.6289.2928.5516.2410.93
Other Current Assets149.69150.78205.53190.74253.11140.7488.3178.8535.62
Total Current Assets6,233.623,991.584,203.415,207.097,613.724,960.691,172.691,943.82913.48
Net Property, Plant & Equipment1,789.871,717.731,419.36955.91705.02465.25335.21169.0462.57
Total Investments and Advances82.51130.9692.3697.06107.6757.092.4813.230.00
Intangible Assets62.7051.0957.1440.7346.795.115.950.787.36
Deferred Tax Assets44.004.20--110.4265.9637.8929.548.04
Other Assets19.9129.5333.0178.5362.1546.6558.0693.2455.38
Total Assets8,232.615,925.105,805.286,379.308,535.345,600.761,612.282,249.661,046.83
Short Term Debt Incl. Current Port. of LT Debt134.71869.10710.32353.01449.48348.9110.818.739.22
Accounts Payable479.04405.00315.11294.78262.39231.96122.49113.2869.78
Income Tax Payable41.6325.9322.9525.1921.3920.3813.455.899.16
Other Current Liabilities1,173.47914.86761.74795.55866.25473.95163.56118.5561.83
Total Current Liabilities1,828.842,214.891,810.111,468.531,599.521,075.20310.31246.45149.99
Long Term Debt1,865.10210.76219.87243.67245.15213.05266.53189.67155.49
Provision for Risks Charges21.7420.2016.127.767.818.110.000.000.00
Deferred Tax Liabilities97.2146.2116.4916.0014.1710.7910.5311.140.37
Other Liabilities29.5370.50171.15221.81489.91375.220.1710.9224.96
Total Liabilities3,842.422,562.562,233.741,957.762,356.561,682.38587.54458.18330.81
Non-Equity Reserves28.9830.3234.2038.1846.3549.1446.3937.8531.80
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4,361.213,332.213,537.334,383.366,132.433,869.25962.201,739.18669.80
Total Shareholders Equity4,361.213,332.213,537.334,383.366,132.433,869.25962.201,739.18669.80
Accumulated Minority Interest0.000.000.000.000.000.0016.1514.4414.42
Total Equity4,361.213,332.213,537.334,383.366,132.433,869.25978.351,753.63684.22
Total Liabilities & Stockholders Equity8,232.615,925.105,805.286,379.308,535.345,600.761,612.282,249.661,046.83
Book Value Per Share39.3431.2233.8242.0259.7342.2415.6129.1311.22
Tangible Book Value Per Share42.1433.6136.5045.6659.2742.1815.5129.1111.09
Full-Time Employees12,00011,00010,0009,0008,2005,3003,5002,200900
Price to Book Ratio8.315.734.994.917.536.1210.624.827.78
Return on Assets4.06-11.00-14.46-26.64-20.65-44.35-49.21-40.84-12.86
Return on Equity7.48-18.78-22.24-37.67-29.19-66.22-70.35-55.89-18.27
Return on Invested Capital4.62-18.21-23.45-43.26-22.89-39.19-77.34-34.90-11.32
Quick Ratio3.081.582.093.354.614.533.697.826.02
Current Ratio3.411.802.323.554.764.613.787.896.09

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income917.69287.69-645.11-880.94-2,001.43-1,459.75-1,603.28-952.21-673.43
Depreciation179.04142.06171.8587.6066.2046.5231.8418.659.89
Other Funds (Non Cash)513.06499.91463.816.42306.10227.91162.78202.10155.45
Funds from Operations1,619.29939.1616.54-786.23-1,627.07-1,181.94-1,436.51-740.71-530.03
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-25.02191.40-157.25-370.22132.23-118.50150.84-10.85-17.20
Income Taxes Payable------2.327.58-3.35
Cash from Operating Activities1,594.271,130.56-140.70-1,156.45-1,494.84-1,300.45-1,285.67-751.56-547.23
Capital Expenditures-141.39-206.38-497.59-580.76-325.05-306.76-117.71-89.77-70.77
Net Assets From Acquisitions0.000.000.000.00-0.00-30.800.00-38.26
Sale of Fixed Assets and Businesses0.000.000.000.00-0.000.004.010.00
Purchase or Sale of Investments-4.33-8.41-16.36655.691,544.38956.78-2,944.39714.00-458.07
Purchase of Investments-11.87-11.87-19.02-16.96-17.38-2,194.29-5,700.20-1,171.31-2,633.32
Sale Or Maturity of Investments7.543.462.66672.651,561.763,151.072,755.811,885.322,175.25
Other Uses-23.77-62.09-34.68-14.99-143.49-8.51-109.69-69.12-69.94
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-169.49-276.89-548.6359.951,075.84641.51-3,202.59559.12-637.04
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock164.72196.8045.4055.6646.913,540.074,332.5647.081,655.47
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock164.72196.8045.4055.6646.913,540.074,332.5647.081,655.47
Proceedsfrom Stock Options0.000.000.000.000.003,447.194,239.300.001,625.84
Issuance or Reduction of Debt, Net101.60889.71145.15360.45-65.86101.67290.1034.7433.55
Change in Long Term Debt802.151,702.96-18.998.8037.3316.86290.1034.7433.55
Issuance of Long Term Debt856.041,742.799.0622.4837.3316.86434.6567.6142.28
Reduction of Long Term Debt-53.89-39.83-28.05-13.680.000.00-144.56-32.87-8.73
Net Financing Active Other Cash Flow-3.37-24.263.000.000.000.00617.900.000.00
Other Financing Activities Uses-3.37-24.260.000.000.000.000.000.000.00
Cash from Financing Activities262.951,062.25193.55416.12-18.953,641.745,240.5581.821,689.02
Exchange Rate Effect73.0160.18-51.73-8.07-69.3014.0518.26-9.53-4.09
Net Change in Cash1,760.731,976.11-547.51-688.45-507.252,996.85770.55-120.14500.66
Free Cash Flow1,452.89944.23-633.61-1,717.85-1,819.89-1,563.74-1,403.38-841.33-617.45
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow29.5536.50-------
Deferred Taxes & Investment Tax Credit-9.4926.000.692.063.38-27.85-9.25-21.93

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments5,844.395,259.264,832.664,588.834,089.852,771.91
Short Term Receivables1,149.091,070.99948.39886.86902.38880.15
Inventories807.90732.63681.61608.23531.69502.88
Other Current Assets129.67153.16138.82149.69140.56155.37
Total Current Assets7,931.057,216.046,601.486,233.625,664.484,310.30
Net Property, Plant & Equipment1,797.201,789.331,786.471,789.871,768.331,761.59
Total Investments and Advances87.1987.6586.9082.51121.34133.71
Intangible Assets37.9260.9661.6862.7063.5864.89
Deferred Tax Assets---44.00--
Other Assets22.3321.9417.3519.9114.8628.02
Total Assets9,875.699,175.918,553.888,232.617,632.586,298.50
Short Term Debt Incl. Current Port. of LT Debt379.59302.14209.47134.71881.27825.66
Accounts Payable496.87470.31423.56479.04383.68360.79
Income Tax Payable14.8076.3263.5241.6311.225.54
Other Current Liabilities1,342.611,270.491,115.021,173.471,092.261,017.89
Total Current Liabilities2,233.872,119.261,811.571,828.842,368.422,209.87
Long Term Debt1,681.711,747.451,843.911,865.101,023.71200.03
Provision for Risks Charges21.5921.5121.8821.7420.6420.90
Deferred Tax Liabilities60.0857.3955.8797.2147.0744.09
Other Liabilities30.0627.6831.3529.5314.3223.49
Total Liabilities4,027.313,973.293,764.573,842.423,474.162,498.39
Non-Equity Reserves28.1228.4628.7228.9829.1029.57
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5,820.265,174.164,760.594,361.214,129.333,770.54
Total Shareholders Equity5,820.265,174.164,760.594,361.214,129.333,770.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5,820.265,174.164,760.594,361.214,129.333,770.54
Total Liabilities & Stockholders Equity9,875.699,175.918,553.888,232.617,632.586,298.50
Book Value Per Share51.0145.7842.8439.3437.3334.32
Tangible Book Value Per Share54.9449.0845.9542.1439.9536.69
Full-Time Employees---12,000--
Price to Book Ratio8.316.657.558.149.937.47
Return on Assets10.498.497.154.061.03-2.96
Return on Equity18.4514.7012.467.481.84-4.98
Return on Invested Capital5.143.433.451.072.432.38
Quick Ratio3.193.063.273.082.171.72
Current Ratio3.553.403.643.412.391.95

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income385.54237.29228.0366.83125.0494.55
Depreciation61.0740.5641.2736.1537.3235.78
Other Funds (Non Cash)132.58115.68122.34142.45140.58128.84
Funds from Operations579.19393.54391.64254.92302.95259.18
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-69.3870.06-189.71164.00100.255.17
Cash from Operating Activities509.81463.60201.94418.93403.20264.35
Capital Expenditures-35.25-27.50-40.91-37.73-48.12-64.12
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.005.860.03-10.21-0.000.00
Purchase of Investments0.000.000.00-11.870.000.00
Sale Or Maturity of Investments0.005.860.031.65-0.000.00
Other Uses-0.59-27.78-4.769.35-1.16-2.95
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-35.84-49.41-45.65-38.60-49.28-67.07
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock110.3211.0523.9519.4180.6533.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock110.3211.0523.9519.4180.6533.38
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-7.86-17.1348.1578.43882.5125.90
Change in Long Term Debt-7.86-17.08-10.23837.32882.49-12.63
Issuance of Long Term Debt0.000.000.00856.04886.750.00
Reduction of Long Term Debt-7.86-17.08-10.23-18.73-4.26-12.63
Net Financing Active Other Cash Flow-0.05-0.05-3.26-0.020.01-24.25
Other Financing Activities Uses-0.05-0.05-3.26-0.020.01-24.25
Cash from Financing Activities102.41-6.1368.8497.83963.1735.03
Exchange Rate Effect10.5219.8619.3823.259.9123.54
Net Change in Cash586.90427.92244.50501.411,327.00255.86
Free Cash Flow474.56436.10161.03381.21355.07220.28
Price to Free Cash Flow29.5524.7530.7637.12--

Revenue breakdown

Collaboration2024: 30.70M 2025: 60.97M
Product2024: 3.78B 2025: 5.28B
All Other Countries Except China, United States Of America, And Switzerland2024: 78.81M 2025: 171.81M
China2024: 1.41B 2025: 1.68B
Europe2024: 362.63M 2025: 611.37M
United States2024: 1.96B 2025: 2.88B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.53%1.6M104.7M386.60K
2026-10-151.73%1.8M103.7M389.72K
2026-09-301.86%1.9M103.7M387.80K
2026-09-151.65%1.7M103.7M372.28K
2026-08-311.37%1.4M103.7M360.33K
2026-08-141.23%1.3M103.7M341.92K
2026-07-310.85%0.9M103.7M307.99K
2026-07-150.91%0.9M101.8M273.61K
2026-06-300.78%0.8M101.8M250.91K
2026-06-150.89%0.9M101.8M235.39K
2026-05-291.07%1.1M101.8M230.95K
2026-05-151.03%1.0M101.8M241.80K
2026-04-301.09%1.1M101.8M239.48K
2026-04-151.14%1.2M101.5M246.52K
2026-03-311.20%1.2M101.5M272.39K
2026-03-131.49%1.5M101.5M286.59K
2026-02-271.35%1.5M110.3M276.05K
2026-02-131.41%1.5M110.1M282.88K
2026-01-301.27%1.4M110.2M297.31K
2026-01-151.23%1.4M110.2M289.32K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call155266.6271.50.003.5130.000.000.973-0.8430.043
call160261.6266.50.003.3820.000.000.972-0.8410.044
call165256.6261.50.003.3110.000.000.972-0.8390.045
call170251.6256.50.003.2140.000.000.971-0.8370.046
call175246.6251.50.003.1200.000.000.970-0.8350.048
call180241.6246.50.003.0290.000.000.969-0.8320.049
call185236.7241.50.002.9410.000.000.968-0.8300.050
call190231.7236.5118.12.8551.000.000.967-0.8270.051
call195226.6231.5113.62.7721.000.000.966-0.8240.053
call200221.6226.5129.892.6901.000.000.965-0.8210.054
call210211.6216.571.202.5332.000.000.963-0.8140.057
call220201.6206.50.002.3840.000.000.960-0.8070.059
call230191.6196.50.002.2410.000.000.958-0.7990.062
call240182186.50.002.1770.000.000.955-0.7900.066
call250172176.543.502.0420.000.000.953-0.7810.069
call260162166.5106.461.9112.000.000.949-0.7710.072
call270152156.90.001.7860.000.000.946-0.7610.076
call280142.1146.981.001.6642.000.000.943-0.7490.080
call290132.2136.940.501.54621.000.000.939-0.7370.084
call300122126.976.091.4325.000.000.934-0.7230.089
call31011211744.551.2562.000.000.929-0.7090.094
call32010210752.451.15111.000.000.924-0.6930.100
call33092.1097.0030.371.1152.000.000.917-0.6750.106
call34082.0087.0023.000.9581.000.000.908-0.6690.115
call35072.0076.9046.700.86813.000.000.899-0.6470.123
call36062.1067.0050.400.7867.000.000.887-0.6340.134
call37052.8057.0041.650.7021520.000.870-0.6260.147
call38043.8047.0040.400.60031.000.000.848-0.6100.163
call39034.7038.0030.700.5581780.000.817-0.6020.185
call40026.2029.5022.500.52144.000.000.764-0.6180.215
call41018.6022.0018.800.49813.001.000.676-0.6770.250
call42012.0015.5013.200.4767193.000.569-0.6970.274
call4306.9010.506.200.46877.000.000.449-0.6810.275
call4403.107.204.000.4845.001.000.339-0.6380.255
call4500.855.004.900.5082.000.000.254-0.5840.223
call4600.004.301.000.5574.000.000.201-0.5590.195
call4700.004.002.350.6271.000.000.174-0.5780.179
call4800.003.802.050.6961.000.000.154-0.5910.165
call4900.003.700.000.7650.000.000.140-0.6090.155
call5000.003.600.000.8300.000.000.128-0.6210.146
call5100.003.500.000.9200.000.000.119-0.6430.138
call5200.003.500.000.9900.000.000.112-0.6610.133
call5300.003.500.001.0560.000.000.107-0.6770.128
call5400.003.501.501.1021.000.000.103-0.6960.125
put1550.003.400.003.1270.000.00-0.017-0.4440.031
put1600.003.400.003.0350.000.00-0.018-0.4430.032
put1650.003.400.002.9450.000.00-0.018-0.4410.032
put1700.003.400.002.8590.000.00-0.019-0.4400.033
put1750.003.401.202.7758.000.00-0.020-0.4380.034
put1800.003.400.002.6940.000.00-0.020-0.4370.035
put1850.003.401.052.6159.000.00-0.021-0.4350.036
put1900.003.402.452.5386.000.00-0.022-0.4330.037
put1950.003.402.602.46321.000.00-0.022-0.4310.038
put2000.003.400.002.3900.000.00-0.023-0.4290.039
put2100.003.400.002.2490.000.00-0.024-0.4250.041
put2200.003.407.652.1141.000.00-0.026-0.4210.043
put2300.003.4011.001.98511.000.00-0.028-0.4160.045
put2400.003.4012.701.8626.000.00-0.029-0.4110.048
put2500.003.402.501.7431.000.00-0.031-0.4060.051
put2600.003.400.441.62812.000.00-0.033-0.4000.053
put2700.003.401.601.5173.000.00-0.036-0.3940.056
put2800.003.403.501.4103.000.00-0.038-0.3870.060
put2900.003.401.861.3067.000.00-0.041-0.3800.063
put3000.003.4020.311.20418.000.00-0.044-0.3730.067
put3100.003.401.481.4151.000.00-0.071-0.6750.094
put3200.003.400.001.3040.000.00-0.076-0.6580.100
put3300.003.401.001.1945530.00-0.083-0.6390.106
put3400.003.500.371.09022.000.00-0.092-0.6320.115
put3500.003.502.100.9401550.00-0.105-0.5880.126
put3600.003.600.800.8834190.00-0.113-0.5940.134
put3700.003.802.900.78226.000.00-0.128-0.5740.146
put3800.004.001.940.69317.000.00-0.152-0.5680.163
put3901.804.5012.150.6101.000.00-0.184-0.5630.185
put4001.505.505.000.54113.0010.00-0.236-0.5740.215
put4103.808.000.000.5150.000.00-0.324-0.6320.250
put4207.6011.400.000.4890.000.00-0.431-0.6510.274
put43012.4016.300.000.4780.000.00-0.551-0.6340.275
put44018.9022.500.000.4750.000.00-0.662-0.5860.254
put45026.7030.400.000.4940.000.00-0.750-0.5220.221
put46034.5039.500.000.5460.000.00-0.796-0.5200.197
put47044.0049.000.000.6050.000.00-0.824-0.5370.180
put48053.6058.500.000.6530.000.00-0.844-0.5500.167
put49063.5068.300.000.7270.000.00-0.858-0.5670.157
put50073.5078.400.000.7760.000.00-0.869-0.5800.148
put51083.5088.400.000.8420.000.00-0.879-0.5880.140
put52093.5098.200.000.9060.000.00-0.886-0.6080.135
put530103.5108.40.000.9680.000.00-0.891-0.6250.130
put540113.5118.40.001.0280.000.00-0.896-0.6410.126

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-16SCHEDULE 13D/ASEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-268-KCurrent report2026-08-26SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-07-30144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.08M2
2026-100022.15M2
2026-090025.15M4
2026-080087.91M6
2026-0700208.07M11
2026-06007.02M19
2026-0500562.03K5
2026-0400103.45K1
2026-0300102.30K1
2026-0200580.20K1
2026-0100220.29K1
2025-120030.87M4
2025-11008.61M5

Institutional holders

Manager% owned
BAKER BROS. ADVISORS LP8.60%
PRIMECAP MANAGEMENT CO/CA/4.90%
Capital International Investors4.12%
FMR LLC2.23%
Capital World Investors2.20%
CITADEL ADVISORS LLC1.39%
PRICE T ROWE ASSOCIATES INC /MD/0.74%
BlackRock, Inc.0.68%
MILLENNIUM MANAGEMENT LLC0.53%
MORGAN STANLEY0.49%

Funds

Fund% owned
New Perspective Fund2.60%
VANGUARD PRIMECAP FUND2.29%
VANGUARD CAPITAL OPPORTUNITY FUND1.16%
New Economy Fund0.84%
EUPAC Fund0.69%
New World Fund Inc0.66%
PRIMECAP Odyssey Aggressive Growth Fund0.63%
Fidelity Growth Company Fund0.60%
PRIMECAP Odyssey Growth Fund0.57%
iShares Biotechnology ETF0.55%

OakChart. ONC. Cached 15 minutes.